Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

643
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
643
Drug Therapy01:28

Drug Therapy

331
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
331
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

792
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
792
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

717
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
717
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.3K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dog- to- dog bite wound management - Comparison of the antiseptic efficacy of polyhexanide and hypochlorous acid with regard to reducing the use of antibiotics: A randomized clinical trial.

Veterinary journal (London, England : 1997)·2025
Same author

Effect of casozepine administration on stress in dogs during a veterinary examination - A randomized placebo-controlled trial.

Veterinary journal (London, England : 1997)·2024
Same author

Saliva Malondialdehyde Concentration of Dogs With and Without Periodontal Disease.

Journal of veterinary dentistry·2024
Same author

Effect of intra-articular platelet-rich plasma or hyaluronic acid on limb function recovery in dogs with TPLO for cranial cruciate ligament rupture: a randomised controlled trial.

The Journal of small animal practice·2024
Same author

Autologous point-of-care stromal vascular fraction transplantation in dogs with advanced osteoarthritis of the knee and hip joints.

Australian veterinary journal·2023
Same author

Carnosinase Gene-Is It Responsible for Diabetic Nephropathy?: Carnosine as a Protective Factor in Diabetic Nephropathy: Association with a Leucine Repeat of the Carnosinase Gene CNDP1. Diabetes 54: 2320-2327, 2005.

Journal of the American Society of Nephrology : JASN·2023

Related Experiment Video

Updated: Mar 2, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

[DGPPN recommendations on quality indicators for schizophrenia].

I Großimlinghaus1, I Hauth2, P Falkai3

  • 1LVR-Institut für Versorgungsforschung, WHO Collaborating Center for Quality Assurance and Empowerment in Mental Health, Medizinische Fakultät, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität, Bergische Landstraße 2, 40629, Düsseldorf, Deutschland.

Der Nervenarzt
|May 10, 2017
PubMed
Summary

The German Association for Psychiatry and Psychotherapy (DGPPN) developed ten quality indicators (QI) for schizophrenia care, focusing on essential aspects and feasibility. These indicators require additional data documentation but are deemed manageable and will undergo further testing.

Keywords:
DGPPNMental disordersPsychiatryQuality indicatorsSchizophrenia

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

Related Experiment Videos

Last Updated: Mar 2, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

Area of Science:

  • Psychiatry
  • Healthcare Quality Management
  • Clinical Indicators

Background:

  • Germany has proposed several quality indicators for mental healthcare.
  • The German Association for Psychiatry and Psychotherapy (DGPPN) Task Force Quality Indicators (QI) focused on developing practical QI for schizophrenia.
  • Previous experience informed the development and pilot testing of these indicators.

Purpose of the Study:

  • To select a set of quality indicators (QI) for schizophrenia applicable to other diagnoses or generic measurements.
  • To prioritize indicators with high feasibility for practical implementation in mental healthcare settings.

Main Methods:

  • A multistage selection process was used by the DGPPN Task Force.
  • 161 existing QI from national and international groups were reviewed.
  • Indicators were adapted in consultation with the DGPPN's "trialogic forum".

Main Results:

  • The DGPPN proposes ten QI for schizophrenia quality measurement.
  • These include monitoring side effects, seclusion/restraint, suicide rates, psychoeducation, timely outpatient treatment post-discharge, aggression management, diagnostic procedures, antipsychotic polypharmacy, and rehabilitation.
  • Specific indicators cover long-term treatment, intervention for significant others, and psychosocial functioning assessment.

Conclusions:

  • Most proposed QI necessitate additional data documentation.
  • The DGPPN estimates the additional data documentation efforts to be manageable but requiring refinancing.
  • The indicators will be validated through feasibility studies in various German mental healthcare hospitals.